SCHEMBL3493577

SCHEMBL3493577

CCn1ccc(C(=O)O)c1C

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 6/20 0.64
MEN1 O00255 1/20 0.42
ABCC4 O15439 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
PTGS1 P23219 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP19A1 P11511 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MYC P01106 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HAAO P46952 1/20 0.36
LPO P22079 2/20 0.36
NR4A1 P22736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19438800 0.82 NOTUM (0.49) NOTUMMEN1ABCC4LMNAPKM
Hydrochloric Acid SCHEMBL3263567 0.81 NOTUM (0.44) NOTUMLMNAKMT2AALDH1A1TDP1
SCHEMBL30774967 0.79 NOTUM (0.54) NOTUMLMNAALDH1A1KDM4E
SCHEMBL8519956 0.79 NOTUM (0.54) NOTUMMEN1KMT2AALDH1A1TDP1
SCHEMBL3492700 0.78 NOTUM (1.00) NOTUMMEN1LMNAKMT2AALDH1A1
SCHEMBL3493724 0.74 NOTUM (0.49) NOTUMMEN1LMNAPKMKMT2A
SCHEMBL5256619 0.74 NOTUM (0.74) NOTUMALDH1A1KDM4E
SCHEMBL16244948 0.73 NOTUM (0.51) NOTUMLMNA
SCHEMBL4562515 0.72 NOTUM (0.55) NOTUMMEN1KMT2AALDH1A1MYC
SCHEMBL3261972 0.72 NOTUM (0.46) NOTUMALDH1A1TDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689047-B Pharmaceutical combination for the treatment of cancer 普莱萨格生命科学公司 2025-03-21 CN disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 NOTUM 1289/4885MEN1 750/4885ABCC4 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.